TORONTO, Nov. 23, 2011 /CNW/ - The Canadian Cancer Research Alliance
(CCRA) announced today the recipients of its inaugural awards, which
recognize contributions to cancer research in Canada.
Dr. Philip E. Branton receives the award for Exceptional Leadership in Cancer Research for his outstanding contributions to the development of the cancer
research community and inter-agency research collaboration in Canada
through the founding of the Canadian Cancer Research Alliance.
Dr. Anthony J. Pawson receives the award for Outstanding Achievements in Cancer Research for his revolutionary work in cancer signal transduction leading to
novel therapies for cancer patients.
Mr. André Picard receives the award for Distinguished Service to Cancer Research for his contributions to public education on cancer research and policy
through exemplary journalism.
"These awards are our way to acknowledge the exceptional contributions
made by these individuals," says Dr. Elizabeth Eisenhauer, Co-Chair of
the CCRA. "We are proud to highlight their achievements and the
remarkable impact they have had on cancer research and the cancer
The awards will be presented during the CCRA's Canadian Cancer Research
Conference being held in Toronto from November 27-30, 2011. For more
information, please go to http://www.ccra-acrc.ca/default_en.htm.
More about Dr. Philip E. Branton, Montréal, QC: Phil Branton is the Gilman Cheney Professor of Biochemistry at the
Faculty of Medicine at McGill University. He chairs the International
Advisory Board of the University Hospital Network (Toronto) and the
Scientific Advisory Committee of the Terry Fox Research Institute. From
2000-2008, Dr. Branton was the inaugural Scientific Director of the
Institute of Cancer Research of the Canadian Institutes of Health
Research. He is founder and a past Chair of the Canadian Cancer
Research Alliance and past Chair of the Research Action Group of the
Canadian Partnership Against Cancer. He was also co-founder of GeminX
Biotechnologies Inc. of Montreal, which had two anti-cancer drugs in
the clinic and was sold recently to Cephalon. Dr. Branton is well known
internationally for basic research on human adenoviruses, cell death,
protein degradation and tumour suppressors. He is a Fellow of the Royal
Society of Canada and was awarded the R.M. Taylor Medal from the
Canadian Cancer Society and the former National Cancer Institute of
Canada in 2005.
More about Dr. Anthony J. Pawson, Toronto, ON: Tony Pawson is a Distinguished Scientist at the Samuel Lunenfeld
Research Institute of Mount Sinai Hospital, and Professor in the
Department of Molecular Genetics at the University of Toronto. His
research has underpinned our understanding of the mechanisms by which
cancer-causing oncoproteins can re-wire cellular signaling networks to
induce inappropriate cell growth and movement, and has revealed new
approaches to targeted therapy. Dr. Pawson has received a number of
awards, including the Robert L. Noble Prize, the AACR/Pezcoller Prize,
the Heineken Prize, the Royal Medal of the Royal Society of London, the
Killam Award, the J. Allyn Taylor Prize, the Louisa Gross Horwitz
Prize, the Wolf Prize in Medicine, and the Kyoto Prize in Basic
Science. He is an Officer of the Order of Canada, and has been
appointed to the Order of Companions of Honour by Queen Elizabeth II.
More about Mr. André Picard, Montréal, QC: André Picard is the public health reporter at The Globe and Mail and the author of three best-selling books. He has received much
acclaim for his writing and for his dedication to improving healthcare.
In 2010 Mr. Picard was awarded the National Newspaper Awards as
Canada's top newspaper columnist. Among his other accolades, André
received the "Outstanding Leadership in Cancer Control Prize" from the
Campaign to Control Cancer and he was named Canada's first "Public
Health Hero" by the Canadian Public Health Association.
The Canadian Cancer Research Alliance
The Canadian Cancer Research Alliance (CCRA) is comprised of 31
organizations that collectively represent the custodians of the
majority of taxpayer dollars and donations devoted to investing in
research that will lead to better ways to prevent, diagnose, and treat
cancer and improve survivor outcomes. Its membership includes federal
research funding programs/agencies, provincial research agencies,
provincial cancer care agencies, and national cancer charities. CCRA is
motivated by the belief that, through effective collaboration, Canadian
cancer research funding organizations can maximize their collective
impact on cancer control and accelerate discovery for the ultimate
benefit of Canadians affected by cancer. The CCRA Secretariat is funded
by the Partnership and the CCRA Board serves as the Partnership's
Research Advisory Group.
The Canadian Cancer Research Alliance is supported by the Canadian Partnership Against Cancer
through a financial contribution from Health Canada.
SOURCE Canadian Cancer Research Alliance
For further information:
For more information or to arrange an interview, please contact:
Canadian Cancer Research Alliance
Tel. (416) 915-9222, ext. 5739
McGill University Media Relations Office
Tel. (514) 398-7698
Samuel Lunenfeld Research Institute
Tel. (416) 586-4800, ext. 2046